{"id":70067,"date":"2026-07-16T15:49:23","date_gmt":"2026-07-16T07:49:23","guid":{"rendered":"https:\/\/flcube.com\/?p=70067"},"modified":"2026-07-16T15:49:24","modified_gmt":"2026-07-16T07:49:24","slug":"chinas-cde-releases-draft-guideline-for-real-world-evidence-based-pediatric-indication-expansion-of-marketed-drugs","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70067","title":{"rendered":"China&#8217;s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">The <strong>Center for Drug Evaluation (CDE)<\/strong> of China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> issued the <strong>Technical Guideline on Communication and Exchange for Real-World Evidence Supporting the Expansion of Pediatric Indications for Marketed Drugs (Draft for Comments)<\/strong> on July 14, 2026. The draft guideline opens a <strong>one-month public comment period<\/strong> and aims to establish a streamlined pathway for expanding pediatric indications using real-world research as the primary evidence source.<\/p>\n\n\n\n<h2 id=\"h-regulatory-framework-key-provisions\" class=\"wp-block-heading\">Regulatory Framework | Key Provisions<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Requirement<\/th><\/tr><\/thead><tbody><tr><td><strong>Comment Period<\/strong><\/td><td>One month from July 14, 2026<\/td><\/tr><tr><td><strong>Primary Evidence Source<\/strong><\/td><td>Real-world research data<\/td><\/tr><tr><td><strong>Target Population<\/strong><\/td><td>Pediatric patients in China<\/td><\/tr><tr><td><strong>Drug Status Requirement<\/strong><\/td><td>Already marketed in China with \u22652 years clinical use<\/td><\/tr><tr><td><strong>Implementation Goal<\/strong><\/td><td>Streamlined, efficient, and implementable regulatory pathway<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-eligibility-criteria-for-drug-candidates\" class=\"wp-block-heading\">Eligibility Criteria for Drug Candidates<\/h2>\n\n\n\n<h3 id=\"h-clinical-urgency\" class=\"wp-block-heading\">Clinical Urgency<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Drugs <strong>urgently needed in pediatric clinical practice<\/strong> in China<\/li>\n\n\n\n<li><strong>Priority support<\/strong> for drugs included in the <strong>Catalogue of Drugs Encouraged for R&amp;D and Application in Children<\/strong><\/li>\n\n\n\n<li>Focus on treatments for <strong>major pediatric diseases<\/strong> including:<\/li>\n\n\n\n<li>Rare diseases<\/li>\n\n\n\n<li>Malignant tumors<\/li>\n\n\n\n<li>Severe infections<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-marketed-status-requirements\" class=\"wp-block-heading\">Marketed Status Requirements<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Must be <strong>approved for marketing in China<\/strong><\/li>\n\n\n\n<li>Require <strong>at least 2 years of actual clinical use records<\/strong><\/li>\n\n\n\n<li>Eligible product types:<\/li>\n\n\n\n<li>Chemical drugs<\/li>\n\n\n\n<li>Therapeutic biologics (excluding cell and gene therapy products)<\/li>\n\n\n\n<li>Traditional Chinese medicines<\/li>\n\n\n\n<li>Must have <strong>robust quality standards<\/strong> and <strong>manufacturing process control systems<\/strong><\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-data-foundation-requirements\" class=\"wp-block-heading\">Data Foundation Requirements<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Applicants must have <strong>preliminary clinical application data<\/strong> in pediatric populations, such as:<\/li>\n\n\n\n<li>Off-label use data<\/li>\n\n\n\n<li>Investigator-initiated clinical trial data<\/li>\n\n\n\n<li><strong>OR<\/strong> have clear access to <strong>high-quality real-world data<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-required-submission-materials\" class=\"wp-block-heading\">Required Submission Materials<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Applicants seeking communication and exchange with CDE must submit comprehensive documentation covering:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Research background and rationale<\/strong><\/li>\n\n\n\n<li><strong>Real-world data sources<\/strong> and <strong>data fitness-for-use assessment<\/strong><\/li>\n\n\n\n<li><strong>Study design<\/strong> and <strong>statistical analysis plan<\/strong><\/li>\n\n\n\n<li><strong>Risk control<\/strong> and <strong>pharmacovigilance plan<\/strong><\/li>\n\n\n\n<li><strong>Study implementation<\/strong> and <strong>quality control<\/strong><\/li>\n\n\n\n<li><strong>Ethics and regulatory compliance<\/strong><\/li>\n\n\n\n<li><strong>Expected outcomes<\/strong> and <strong>regulatory communication plan<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-strategic-implications\" class=\"wp-block-heading\">Market Impact &amp; Strategic Implications<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">This draft guideline represents a significant step toward addressing the critical gap in pediatric drug availability in China, where an estimated <strong>70% of medications used in children lack formal pediatric indications<\/strong>. By leveraging real-world evidence, the CDE aims to accelerate access to essential medicines while maintaining rigorous safety and efficacy standards.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">For pharmaceutical companies with established adult products, this framework creates a <strong>lower-barrier pathway<\/strong> to expand into the pediatric market without conducting full-scale randomized controlled trials. Companies with robust real-world data collection systems and existing pediatric off-label use patterns stand to benefit most from this regulatory evolution.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The emphasis on <strong>rare diseases, pediatric cancers, and severe infections<\/strong> aligns with China&#8217;s broader healthcare priorities and may incentivize increased investment in these underserved therapeutic areas.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory developments and market opportunities. Actual implementation and impact may vary based on final guideline adoption, regulatory interpretations, and market dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Center for Drug Evaluation (CDE) of China&#8217;s National Medical Products Administration (NMPA) issued the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[4],"tags":[102,14,68],"class_list":["post-70067","post","type-post","status-publish","format-standard","hentry","category-policy-regulatory","tag-cde","tag-nmpa","tag-pediatric-drugs"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>China&#039;s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The Center for Drug Evaluation (CDE) of China&#039;s National Medical Products Administration (NMPA) issued the Technical Guideline on Communication and Exchange for Real-World Evidence Supporting the Expansion of Pediatric Indications for Marketed Drugs (Draft for Comments) on July 14, 2026. The draft guideline opens a one-month public comment period and aims to establish a streamlined pathway for expanding pediatric indications using real-world research as the primary evidence source.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70067\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"China&#039;s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs\" \/>\n<meta property=\"og:description\" content=\"The Center for Drug Evaluation (CDE) of China&#039;s National Medical Products Administration (NMPA) issued the Technical Guideline on Communication and Exchange for Real-World Evidence Supporting the Expansion of Pediatric Indications for Marketed Drugs (Draft for Comments) on July 14, 2026. The draft guideline opens a one-month public comment period and aims to establish a streamlined pathway for expanding pediatric indications using real-world research as the primary evidence source.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70067\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-16T07:49:23+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-16T07:49:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70067#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70067\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"China&#8217;s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs\",\"datePublished\":\"2026-07-16T07:49:23+00:00\",\"dateModified\":\"2026-07-16T07:49:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70067\"},\"wordCount\":462,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"CDE\",\"NMPA\",\"Pediatric drugs\"],\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70067#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70067\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70067\",\"name\":\"China's CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-16T07:49:23+00:00\",\"dateModified\":\"2026-07-16T07:49:24+00:00\",\"description\":\"The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) issued the Technical Guideline on Communication and Exchange for Real-World Evidence Supporting the Expansion of Pediatric Indications for Marketed Drugs (Draft for Comments) on July 14, 2026. The draft guideline opens a one-month public comment period and aims to establish a streamlined pathway for expanding pediatric indications using real-world research as the primary evidence source.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70067#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70067\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70067#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"China&#8217;s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"China's CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs - Insight, China&#039;s Pharmaceutical Industry","description":"The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) issued the Technical Guideline on Communication and Exchange for Real-World Evidence Supporting the Expansion of Pediatric Indications for Marketed Drugs (Draft for Comments) on July 14, 2026. The draft guideline opens a one-month public comment period and aims to establish a streamlined pathway for expanding pediatric indications using real-world research as the primary evidence source.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70067","og_locale":"en_US","og_type":"article","og_title":"China's CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs","og_description":"The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) issued the Technical Guideline on Communication and Exchange for Real-World Evidence Supporting the Expansion of Pediatric Indications for Marketed Drugs (Draft for Comments) on July 14, 2026. The draft guideline opens a one-month public comment period and aims to establish a streamlined pathway for expanding pediatric indications using real-world research as the primary evidence source.","og_url":"https:\/\/flcube.com\/?p=70067","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-16T07:49:23+00:00","article_modified_time":"2026-07-16T07:49:24+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70067#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70067"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"China&#8217;s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs","datePublished":"2026-07-16T07:49:23+00:00","dateModified":"2026-07-16T07:49:24+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70067"},"wordCount":462,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["CDE","NMPA","Pediatric drugs"],"articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70067#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70067","url":"https:\/\/flcube.com\/?p=70067","name":"China's CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-16T07:49:23+00:00","dateModified":"2026-07-16T07:49:24+00:00","description":"The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) issued the Technical Guideline on Communication and Exchange for Real-World Evidence Supporting the Expansion of Pediatric Indications for Marketed Drugs (Draft for Comments) on July 14, 2026. The draft guideline opens a one-month public comment period and aims to establish a streamlined pathway for expanding pediatric indications using real-world research as the primary evidence source.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70067#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70067"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70067#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"China&#8217;s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70067","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70067"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70067\/revisions"}],"predecessor-version":[{"id":70068,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70067\/revisions\/70068"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70067"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70067"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70067"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}